A phase II study of toremifene in carcinoma corporis uteri. Preliminary communication.
A phase II study of toremifene was started in patients suffering from advanced carcinoma corporis uteri. Minimum duration of treatment was 3 months but with stabilized disease (SD) and remission the treatment is to be continued as long as the treatment response lasts. At present four patients with recurrent carcinoma corpus uteri have been included. Dose level of toremifene is 200 mg per day. At 12 weeks one of the patients has partial remission (PR), two have SD and one progressive disease (PD). There have been no unacceptable side effects.
Horváth
G
G
Oncologic Department, Lund University Hospital, Sweden.
Tropé
C
C
Almbo
H E
HE
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017312:Toremifene; D014594:Uterine Neoplasms / Q000188:drug therapy*
D004965:Estrogen Antagonists; D013629:Tamoxifen; D017312:Toremifene